BioWorld

July 7, 2006

MGI Sells Dacogen Rights Ex-North America To Cilag

Two months after receiving FDA approval for Dacogen to treat myelodysplastic syndromes, MGI Pharma Inc. licensed rights to the drug outside North America to Cilag GmbH. (BioWorld Today) Read More

Alnylam's Amended Merck Deal Worth Up To $120M In Payments

Tethers, Combination Therapy Suggest T-Cell Use In Cancer

Valera Seeking Approval For Annual Implant To Fight CPP

Ambrx's Series C Adds $52M To Advance Lead Candidates

Clinic Roundup

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...